SK Biopharmaceuticals signs KRW 63.31 billion drug supply deal with SK Life Science Inc

By Public Technologies
  • SK Biopharmaceuticals signed a drug supply contract valued at KRW 63.31 billion to supply cenobamate (XCOPRI) for US sales.
  • Counterparty SK Life Science is its US subsidiary, making the deal an internal transaction not recognized as consolidated revenue.
  • Contract value reflects USD 46.55 million converted at KRW 1,360 per USD, excluding VAT.
  • Order date was Sept. 23, 2026; contract runs Sept. 23-25, 2026; payment due within 120 days of delivery.
  • Deal equals 9% of 2025 consolidated revenue of KRW 706.74 billion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SK Biopharmaceuticals Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20260923800342), on September 23, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.